Ivospemin (SBP-101) is a proprietary polyamine analogue that accumulates in the pancreatic acinar cells due to its unique chemical structure. Laboratory studies suggest the primary mechanism of action of ivospemin is driven by its enhanced uptake in pancreatic cancer cells and, potentially, other cancer cell types, resulting in disruption of normal polyamine metabolism. ivospemin (SBP-101) is also taken up preferentially by the exocrine pancreas, the liver and kidneys. Importantly, pancreatic islet cells, which secrete insulin and are structurally and functionally dissimilar to acinar cells, are not impacted by ivospemin (SBP-101).
CPP-1X (Eflornithine HCl [the monohydrochloride monohydrate of 2-(difluoromethyl) ornithine or DFMO]) is a potent, enzyme-activated, irreversible inhibitor of the enzyme ornithine decarboxylase (ODC), the first and rate-limiting enzyme in the biosynthesis of polyamines.
Flypovi™ is the combination of CPP-1X and Sulindac. Sulindac and its metabolites function through their effects on cyclooxygenases and prostaglandin metabolism, but also on non-cyclooxygenase mechanisms. Sulindac induces the expression of the spermidine/spermine N-acetyltransferase SAT1, a polyamine catabolic gene product implicated in polyamine export via the transcriptional activation of SAT1 by a peroxisomal proliferator-activated receptor gamma. This stimulates polyamine export and catabolism. Hence the combination of Flynpovi™ inhibits the de novo generation of polyamines thru ODC inhibition and increasing the export and catabolism of polyamines with sulindac.